Autolus Therapeutics (AUTL) Registration filing summary

Company overview and business model

• Early commercial-stage biopharmaceutical company focused on next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.

• Lead product AUCATZYL (obe-cel) approved by FDA in November 2024 for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL); commercial launch in US in January 2025.

• Conditional marketing authorization for AUCATZYL in the UK (April 2025) and EU (July 2025); launched in UK in January 2026, but EU launch on hold for 2026.

• Ongoing clinical development of obe-cel in pediatric B-ALL, B-NHL, and autoimmune diseases such as lupus and multiple sclerosis.

• Manufacturing centralized at the Nucleus facility in Stevenage, UK, with Cardinal Health as US distribution partner.

Financial performance and metrics

• Registration statement allows for the issuance of up to $150,000,000 in securities, including ordinary shares, ADSs, debt securities, and warrants.

• ADSs traded on Nasdaq under symbol "AUTL"; closing price on April 9, 2026, was $1.47 per ADS.

Use of proceeds and capital allocation

• Net proceeds intended for continued clinical development, manufacturing, commercialization of product candidates, and general corporate purposes such as working capital, capital expenditures, investments, acquisitions, and collaborations.

• Management retains broad discretion over allocation of proceeds; may invest proceeds in short-term, investment-grade, interest-bearing securities pending use.